Home › Heart Valve Diseases › NCT06917586
Mosaic Mitral Valve: Long-Term Outcomes in Patients Under 65
Long Term Patient Outcomes and Product Durability of the Mosaic Mitral Valve Bioprosthesis in Patients Under 65
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Inclusion Criteria: * Received the Mosaic Mitral Valve Bioprosthetic at ProMedica Toledo Hospital * Under the age of 65 Exclusion Criteria: * Over the age of 65 * Under the age of 18 * Surgery performed at institutions outside of ProMedica Toledo Hospital
About the study
The safety and efficacy of the Mosaic bioprosthetic heart valves for cardiac valve replacement in the aortic position has been well documented throughout the literature. However, few studies assessing structural valve deficiency, patient outcomes and overall product performance in patients under the age of 65 exists for the Mosaic mitral valve bioprosthetic. This study aims to assess valve efficacy, stability, and post operative outcomes in patients who have received the Mosaic mitral valve prothesis at ProMedica Toledo Hospital and were under the age of 65.
Sponsor: Michael Moront · Participants: 300 · Started: Jan 1, 2025
Contact the study team
- Dawn Muskiewicz, MS · Phone: 419-291-7517
- Leah Stevenson, MS · Phone: 419-291-3419
Official record on ClinicalTrials.gov — NCT06917586
Locations in the U.S.
| Ohio | ProMedica Toledo Hospital, Toledo |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.